These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10152542)

  • 1. AIDS in the 1990s: managing a decade-long disease.
    Naper J
    Hosp Technol Ser; 1995 Oct; 14(12):5-6. PubMed ID: 10152542
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic and virologic markers determining progression to AIDS.
    Schellekens PT; Koot M; Roos MT; Tersmette M; Miedema F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S62-6. PubMed ID: 7552515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical effectiveness of zidovudine].
    Mulder JW
    Ned Tijdschr Geneeskd; 1995 Feb; 139(5):211-3. PubMed ID: 7854480
    [No Abstract]   [Full Text] [Related]  

  • 4. [AIDS: everybodies business].
    Joubin R; Gougeon F; Le Fresne C; Le Heno P; Marquis B; Ronxin P; Seven F; Briand Y; Dejour R; Gicquel EJ
    Rev Infirm; 1998 Apr; (37):51-6. PubMed ID: 9601425
    [No Abstract]   [Full Text] [Related]  

  • 5. AIDS. Virological mayhem.
    Wain-Hobson S
    Nature; 1995 Jan; 373(6510):102. PubMed ID: 7816085
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
    Tierney C; Lathey JL; Christopherson C; Bettendorf DM; D'Aquila RT; Hammer SM; Katzenstein DA
    J Infect Dis; 2003 Jan; 187(1):144-8. PubMed ID: 12508159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
    Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
    Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of antiretroviral therapy on AIDS and survival.
    Lundgren JD; Mocroft A
    J HIV Ther; 2006 Jun; 11(2):36-8. PubMed ID: 16981594
    [No Abstract]   [Full Text] [Related]  

  • 9. A review and update on HIV infection and the AIDS epidemic in the adolescent and adult.
    Kahn MA
    J Tenn Dent Assoc; 2000; 80(4):21-7. PubMed ID: 11323867
    [No Abstract]   [Full Text] [Related]  

  • 10. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death.
    Hill AM; DeMasi R; Dawson D
    Antivir Ther; 1998; 3(3):139-45. PubMed ID: 10682131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia.
    Sabin CA; Devereux HL; Clewley G; Emery VC; Phillips AN; Loveday C; Lee CA; Griffiths PD
    J Infect Dis; 2000 May; 181(5):1800-3. PubMed ID: 10823788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Linking Nef with the immunological and virological determinants of AIDS].
    Gómez-Icazbalceta G; Larralde C
    Rev Invest Clin; 2009; 61(3):243-51. PubMed ID: 19736813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.
    Blattner WA; Oursler KA; Cleghorn F; Charurat M; Sill A; Bartholomew C; Jack N; O'Brien T; Edwards J; Tomaras G; Weinhold K; Greenberg M
    J Infect Dis; 2004 May; 189(10):1793-801. PubMed ID: 15122515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease.
    Sterling TR; Hoover DR; Astemborski J; Vlahov D; Bartlett JG; Schupbach J
    J Infect Dis; 2002 Oct; 186(8):1181-5. PubMed ID: 12355373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV heterogeneity and disease progression in AIDS: a model of continuous virus adaptation.
    Lukashov VV; Goudsmit J
    AIDS; 1998; 12 Suppl A():S43-52. PubMed ID: 9632983
    [No Abstract]   [Full Text] [Related]  

  • 16. [HIV and AIDS: experiencing the symptoms. What cell count and viral burden do not tell us].
    Holzhemer WL
    Servir; 2003; 51(3):127-32. PubMed ID: 12889249
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine.
    Dykes C; Najjar J; Bosch RJ; Wantman M; Furtado M; Hart S; Hammer SM; Demeter LM
    J Infect Dis; 2004 Mar; 189(6):1091-6. PubMed ID: 14999613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.